Software Engineering Manager

CoMind publishes first peer-reviewed papers in Neurophotonics, establishing the science behind non-invasive cerebral blood flow monitoring. The two companion papers outline the theoretical foundations and technical performance of CoMind's time-resolved interferometric optical neuromonitoring technology and demonstrate a device that meets the standard for clinical translation. CoMind today announced the publication of its first two peer-reviewed papers in Neurophotonics, a leading journal in the biomedical optics research field. These companion papers represent the culmination of several years of work by the CoMind team and together lay out both the scientific rationale for the company's chosen approach and the experimental evidence that its research prototype, CoMind R1, delivers on the performance required for clinical-grade non-invasive monitoring of cerebral blood flow (CBF). Continuous, bedside monitoring of cerebral blood flow remains one of the most significant unmet needs in critical care. Despite decades of research, no non-invasive technology for the continuous monitoring of CBF has yet achieved routine clinical use. CoMind's technology addresses this challenge by employing a time-of-flight (ToF) resolved optical sensing method that provides depth-resolved sensitivity to blood flow dynamics. Paper 1: setting the performance target. The first paper led by Dr. Dominic Hill: "Monte Carlo simulations of time-resolved blood flow index: times-of-flight beyond ~1 ns are necessary for brain-dominated measurements," provides a rigorous quantitative assessment of in what circumstances speckle-based optical measurements of CBF become genuinely brain-dominated rather than dominated by superficial signals. Using Monte Carlo simulations at 1064 nm, validated against both phantom and in-vivo data, the CoMind team systematically evaluated the contribution of different tissue layers as a function of source-detector separation, time-of-flight gate, and autocorrelation time-lag. The findings are clear and consequential: for a typical adult, a ToF of approximately 1 ns or greater is required to ensure the measured signal is dominated by cerebral rather than extracerebral tissue. To meet this threshold for the 85th percentile of adult brain depths, the required ToF gate rises to 1.2 ns. Paper 2: A device that meets the target. The second paper, led by Veronika Parfentyeva: "CoMind R1: A time-resolved interferometric optical neuromonitoring system for pulsatile cerebral blood flow measurement at late times-of-flight," describes the design, construction, and validation of CoMind's research prototype (CoMind R1), and demonstrates that it achieves the performance targets identified in the first paper CoMind R1 integrates a high-power, linearly-swept 1064 nm laser with multimode fibre collection, parallelised detection, and real-time signal processing. The system achieves an instrument response function width of just 120 picoseconds and exhibits no significant drift over 24 hours of continuous operation. In a study of 25 healthy adults, CoMind R1 consistently produced high-quality pulsatile cerebral blood flow waveforms at times-of-flight averaging 1.2 ns - exceeding the prior art and meeting the threshold identified in the companion simulation paper. In a separate experiment, visual stimulation produced significant, ToF-dependent haemodynamic responses in the visual cortex, directly demonstrating both brain sensitivity and tissue selectivity: CoMind R1 can not only measure CBF but distinguish it from superficial tissue blood flow. A foundation for clinical translation. Together, these two peer-reviewed papers form an integrated foundation for CoMind's work. The simulation paper establishes the level of device performance needed for clinical translation; while the device paper demonstrates that CoMind R1 achieves that performance in a scalable, robust architecture. CoMind's ongoing focus is to build on this exceptional foundation and achieve an optimised, multi-parameter neuromonitoring technology - CoMind One - ready for launch in 2027. To quote Chief Scientific Officer, Dr. Rob Cooper: "These papers are a huge milestone for CoMind and represent the culmination of years of technical development across multiple domains. The first paper outlines the fundamental arguments in favour of the optical sensing approach we have chosen to pursue, and makes clear the level of performance needed for clinical translation. The second paper shows that we are already achieving that target."

CoMind secures over $100 million to advance breakthrough brain-monitoring technology. CoMind's latest $102.5 million funding round marks a major step forward for European health innovation. The london-based company is developing a non-invasive device that could make brain monitoring as routine as measuring blood pressure. Its success reflects the growing investor appetite Kylla observes for breakthrough medtech ventures that combine science, technology, and strong commercial potential. London-based health-technology company CoMind has secured $102.5 million in funding to advance its pioneering non-invasive brain-monitoring device towards market launch in 2027. The new round, led by venture capital firm Plural, will support clinical validation and regulatory approval processes in the United States. At Kylla, Kylla Europe closely follow and engage with the fast-growing European medtech and digital-health sectors. CoMind's successful capital raise reflects the strong investor appetite Kylla Europe has seen among its international partners for innovative, AI-driven medical technologies that improve patient outcomes and healthcare efficiency. Founded in 2018 by James Dacombe, CoMind is developing a medical device that can measure blood flow and pressure in the brain without surgery. Using low-powered infrared lasers and advanced data processing, the system can monitor cerebral blood flow, intracranial pressure, and autoregulation - vital metrics in cases of trauma, stroke, or cardiac surgery. The technology aims to make neurological monitoring as routine as measuring blood pressure. The company has already conducted successful clinical trials in Barcelona and London, publishing research that demonstrates the safety and accuracy of its system. It is now preparing for a pivotal third clinical study in the United States as part of its submission to the Food and Drug Administration. Taavet Hinrikus, co-founder of Wise and partner at Plural, praised Dacombe's unconventional approach to innovation, drawing parallels with other transformative entrepreneurs who entered new industries with fresh perspectives. The investment marks a strong vote of confidence in both the science and scalability of CoMind's technology. Kylla remains committed to fostering relationships across the global health-innovation ecosystem and supporting visionary founders on their journey from early-stage funding to international expansion. The CoMind case exemplifies how patient-focused innovation, backed by strategic investors, can redefine entire segments of the healthcare market. At Kylla, confidentiality and trust are central to its relationships with investors, portfolio companies and clients. Kylla Europe do not publicly share transaction details, respecting both financial sensitivities and the competitive interests of the businesses Kylla Europe is involved with. This story is not a report on Kylla's direct involvement but highlights a deal that aligns with the type of investments Kylla Europe focus on and strongly identify with.